Back
ESC Professional Premium Access

Real-world data from the use of ranolazine in patients with stable angina pectoris: the RANGER study

Session: Coronary artery disease - Pharmacotherapy 3
Topic: Pharmacotherapy
Speaker: Doctor P. STAFYLAS (Thessaloniki, GR)
Event: ESC Congress 2022

Congress Presentation

Add to my library

Like

About the speaker

Doctor Panagiotis STAFYLAS

HealThink, Thessaloniki (Greece)
1 follower

6 more presentations in this session

Effect of exercise-based cardiac rehabilitation on the ischemic threshold in patients with high-risk ischemic heart disease

Speaker: Doctor J. Lara Vargas (Ciudad de Mexico, MX)

Access
Abstract
Slides
Like
Thumbnail

Impact of different antiplatelet therapy cessation modes on outcomes in patients treated with ticagrelor with or without aspirin after PCI: the twilight-antiplatelet cessation study

Speaker: Doctor A. Spirito (New York, US)

Access
Abstract
Slides
Like
Thumbnail

Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis of cohort studies

Speaker: Mr S. Soulaidopoulos (Athens, GR)

Access
Abstract
Slides
Like
Thumbnail

Low dose rivaroxaban therapy in aspirin allergic patients undergoing percutaneous coronary intervention

Speaker: Doctor S. Manjooran (London, GB)

Access
Abstract
Slides
Like
Thumbnail

Lipoprotein(a), cardiovascular events, and benefit of P2Y12 inhibition: insights from the PEGASUS-TIMI 54 trial

Speaker: Doctor S. Patel (Boston, US)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Coronary artery disease - Pharmacotherapy 3

Speakers: Doctor P. STAFYLAS, Doctor J. Lara Vargas, Doctor A. Spirito, Mr S. Soulaidopoulos, Doctor S. Manjooran...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources